AllSci News
Cystic Fibrosis Foundation backs SpliSense's Phase IIb push with USD 13m for orphan CF mutation
Israel-based SpliSense announced a funding agreement with the Cystic Fibrosis Foundation under which the Foundation will provide up to USD 13 million to...
SSY Group pivots to renal therapeutics via license to Opterion's osmotic agent
SSY Group's subsidiary has signed a letter of intent to license OPT101, a novel non-glucose osmotic agent for peritoneal dialysis, from Switzerland-based...
Otsuka and Harbour BioMed expand T-cell engager into autoimmune diseases beyond cancer
Otsuka and Harbour BioMed Move BCMAxCD3 T-Cell Engager HBM7020 into First-in-Human Autoimmune Trial
AviadoBio converts neurology-only gene therapy license into universal platform across all human diseases
UK-based AviadoBio has expanded its exclusive license agreement with King's College London, converting a neurology-only platform license into a universal IP...
Qihan’s dual-target CD19/BCMA CAR-T achieves FDA’s “triple crown” for autoimmune diseases
China-based Hangzhou Qihan Biotech Co., Ltd. announced that QT-019B, its allogeneic dual-target chimeric antigen receptor T (CAR-T) cell therapy, has received both…
Zai Lab’s DLL3 ADC Zoci secures EMA orphan designation for SCLC
Zai Lab’s zocilurtatug pelitecan has secured EMA Orphan Drug Designation (ODD) for pulmonary neuroendocrine carcinomas (NECs), a category dominated by small cell…
Merck bets USD 510m on Protillion’s protein engineering platform for biologics discovery
California-based Protillion Biosciences, Inc. and Merck (NYSE: MRK) have announced a multi-target drug discovery collaboration and license agreement that gives Merck access…
Italy's Thena launches first-in-human test of TfR1-aimed ferritin nanoparticle drug delivery
Italian biotech Thena Biotech S.r.l. has initiated [a first-in-human Phase I trial](https://app.allsci.com/clinical-trial/ASC-CT-0000001278980-1.0-1781270749) of THE-0504, an engineered human ferritin nanoparticle loaded with the topoisomerase I inhibitor Genz-644282, in patients with heavily pretreated solid tumors. The trial is notable for applying a conditionally activatable protein nanocage —
Lilly deepens pain strategy with acquisition of MNK inhibitor developer 4E Therapeutics
Eli Lilly's acquisition of Austin, Texas-based 4E Therapeutics, Inc. adds a first-in-class oral MNK inhibitor to its expanding non-opioid pain pipeline,...
Takeda strengthens oveporexton's case ahead of FDA decision with new Phase III narcolepsy data
With a US FDA decision expected in Q3 2026, Takeda (TSE:4502/NYSE:TAK) presented secondary and exploratory endpoint data from its two pivotal Phase III...
NovaBridge’s givastomig earns FDA Fast Track in gastric cancer
Maryland-based NovaBridge Biosciences (Nasdaq: NBP) announced that the US FDA has granted Fast Track Designation to givastomig (TJ033721 / ABL111), a Claudin…
Dimerix adds China, SE Asia partner for Phase III CCR2 antagonist with USD 340m Everest deal
Australia-based Dimerix Limited (ASX: DXB) has completed its fifth and final major territorial licensing transaction for its Phase III kidney disease...
FDA accepts Gilead's once-weekly oral lenacapavir as first long-acting HIV PrEP pill
The US FDA's acceptance of a supplemental New Drug Application (sNDA) for once-weekly oral lenacapavir as pre-exposure prophylaxis (PrEP) represents a...
UCSF explores molecular drivers of pulmonary veno-occlusive disease
University of California, San Francisco has received a USD 1.63 million NIH R01 grant from the National Heart, Lung, and Blood Institute to investigate the...
Mayo Clinic expands multi-ethnic blood biomarker effort for Alzheimer's disease
Mayo Clinic Jacksonville has received a USD 8.16 million National Institute on Aging U19 renewal grant to advance blood-based biomarker discovery for...
The AllSci Brief
Systematic R&D and deal news. Daily.